The independent data management committee on the Intracept randomized controlled trial (RCT) has halted the study for efficacy at a prespecified interim analysis. The clinical trial found that for a specific kind of lower back pain, patients had a significant average reduction in pain at three months after treatment. The study found that treatment with the minimally invasive Intracept intraosseous nerve ablation system, which is from Minneapolis-based Relievant Medsystems Inc., was superior vs. non-surgical pain management.

New York-based Tara Biosystems Inc. has staked its claim to offering a functional representation of the human heart that is the closest, most accurate one that is currently marketed. To help back that up, its technology, the Biowire II platform, has been assessed for the first time by researchers in a peer-reviewed journal.